9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Dendritic Cell-based Immunotherapy in Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Dendritic Cell-based Immunotherapy in Mesothelioma

Dendritic Cell-based Immunotherapy in Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 10

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: safety,  tolerability,  ,

Interventions: tumor lysate-loaded autologous dendritic cells,

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: September 2009

Completion Date: September 2009

Last  Posted Date: November 16, 2010

Location: Department of Pulmonary Medicine, Rotterdam, Zuid-Holland, Netherlands

Website Link: https://ClinicalTrials.gov/show/NCT00280982

Was this article helpful?
Dislike 0